Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 10/20 | 0.83 |
| ▸ | HTR1A | P08908 | 5/20 | 0.65 |
| ▸ | HTR7 | P34969 | 4/20 | 0.65 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.63 |
| ▸ | DRD2 | P14416 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060680 | 0.91 | PARP1 (1.00) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL29831539 | 0.88 | PARP1 (0.66) | PARP1HTR1AHTR7PARP2DRD2 | |
| SCHEMBL16404338 | 0.82 | PDE10A (0.84) | PARP1PARP2PDE10A | |
| SCHEMBL29370038 | 0.80 | HTT (0.70) | PARP1HTR1AHTR7DRD2 | |
| SCHEMBL14585685 | 0.80 | GAA (0.78) | — | |
| SCHEMBL6646136 | 0.78 | PDE10A (0.67) | PARP1PARP2PDE10A | |
| SCHEMBL14981676 | 0.78 | PARP1 (1.00) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL9010033 | 0.78 | TNKS (0.71) | PARP1PARP2DRD2 | |
| SCHEMBL23068618 | 0.77 | PARP1 (0.59) | PARP1HTR1AHTR7PARP2 | |
| SCHEMBL6796582 | 0.77 | GAA (0.76) | PARP1HTR1AHTR7PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| WO-2023282702-A1 | SHP2 INHIBITOR AND USE THEREOF | 주식회사 카나프테라퓨틱스 | 2023-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | PARP1 4212/4885HTR1A 4644/4885HTR7 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.